Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

被引：2
|
作者：
Eide, Christopher A. [1 ]
Brewer, Diana [1 ]
Xie, Tao [2 ]
Schultz, Anna Reister [1 ]
Savage, Samantha L. [1 ]
Muratcioglu, Serena [3 ]
Merz, Noah [1 ]
Press, Richard D. [4 ]
O'Hare, Thomas [5 ]
Jacob, Thomas [6 ]
Vu, Tania Q. [6 ,7 ]
Tognon, Cristina E. [1 ]
Macey, Tara A. [1 ]
Kuriyan, John [3 ,8 ]
Kalodimos, Charalampos G. [2 ]
Druker, Brian J. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97239 USA
[2] St Jude Childrens Res Hosp, Dept Struct Biol, Memphis, TN USA
[3] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN USA
[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Pathol, Portland, OR USA
[5] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[6] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR USA
[7] Oregon Hlth & Sci Univ, Ctr Spatial Syst Biosci, Portland, OR USA
[8] Vanderbilt Coll Arts & Sci, Dept Chem, Nashville, TN USA
来源：
CANCER CELL | 2024年 / 42卷 / 09期
关键词：
PROTEIN;
D O I：
10.1016/j.ccell.2024.08.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1486 / 1488
页数：3
相关论文
共 50 条
  • [1] BCR-ABL1 mutation ≠ ponatinib resistance
    Saglio, Giuseppe
    Fava, Carmen
    BLOOD, 2016, 127 (06) : 666 - +
  • [2] Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
    Qiang, W.
    Antelope, O.
    Zabriskie, M. S.
    Pomicter, A. D.
    Vellore, N. A.
    Szankasi, P.
    Rea, D.
    Cayuela, J. M.
    Kelley, T. W.
    Deininger, M. W.
    O'Hare, T.
    LEUKEMIA, 2017, 31 (12) : 2844 - 2847
  • [3] Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
    W Qiang
    O Antelope
    M S Zabriskie
    A D Pomicter
    N A Vellore
    P Szankasi
    D Rea
    J M Cayuela
    T W Kelley
    M W Deininger
    T O’Hare
    Leukemia, 2017, 31 : 2844 - 2847
  • [4] Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia
    Gibbons, Don L.
    Pricl, Sabrina
    Posocco, Paola
    Laurini, Erik
    Fermeglia, Maurizio
    Talpaz, Moshe
    Cortes, Jorge E.
    Donato, Nicholas J.
    Quintas-Cardama, Alfonso
    BLOOD, 2013, 122 (21)
  • [5] Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants
    Eide, Christopher A.
    Zabriskie, Matthew S.
    Savage, Samantha L.
    Antelope, Orlando
    Vellore, Nadeem A.
    Than, Hein
    Schultz, Anna Reister
    Clair, Phillip M.
    Bowler, Amber D.
    Pomicter, Anthony D.
    Yan, Dongqing
    Senina, Anna V.
    Wang, Qiang
    Kelley, Todd W.
    Szankasi, Philippe
    Heinrich, Michael C.
    Tyner, Jeffrey W.
    Rea, Delphine
    Cayuela, Jean-Michel
    Kim, Dong-Wook
    Tognon, Cristina E.
    O'Hare, Thomas
    Druker, Brian J.
    Deininger, Michael W.
    BLOOD, 2019, 134
  • [6] Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
    Rea, Delphine
    Hughes, Timothy P.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 171
  • [7] Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
    Deininger, Michael W.
    Hodgson, J. Graeme
    Shah, Neil P.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Nicolini, Franck E.
    Talpaz, Moshe
    Baccarani, Michele
    Mueller, Martin C.
    Li, Jin
    Parker, Wendy T.
    Lustgarten, Stephanie
    Clackson, Tim
    Haluska, Frank G.
    Guilhot, Francois
    Kantarjian, Hagop M.
    Soverini, Simona
    Hochhaus, Andreas
    Hughes, Timothy P.
    Rivera, Victor M.
    Branford, Susan
    BLOOD, 2016, 127 (06) : 703 - 712
  • [8] BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB
    Byrgazov, K.
    Lucini, C.
    Printz, D.
    Koenig, M.
    Valent, P.
    Hantschel, O.
    Lion, T.
    HAEMATOLOGICA, 2017, 102 : 233 - 233
  • [9] Dynamic Evolution of Ponatinib Resistant BCR-ABL1 T315 and Compound Mutations
    Chen, Jiaqi
    Liu, Hongxing
    Wang, Fang
    Zhang, Yang
    Chen, Xue
    Nie, Daijing
    Li, Yu
    Tan, Yincheng
    Xu, Yuanli
    Ma, Xiaoli
    BLOOD, 2019, 134
  • [10] BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib
    Byrgazov, Konstantin
    Lucini, Chantal Blanche
    Valent, Peter
    Hantschel, Oliver
    Lion, Thomas
    HAEMATOLOGICA, 2018, 103 (01)
12345